No Detail Found!

Assessment of WT1 Expression as a Marker of Treatment Outcome in Karyotype Normal Acute Myeloid Leukemia Patients in Pakistan.

Author(s)
Zeeshan Ansar Ahmed Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Karachi, Pakistan
Muhammad Shariq Shaikh Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Karachi, Pakistan
Tariq Moatter Department of Pathology and Laboratory Medicine, The Aga Khan University Hospital, Karachi, Pakistan
Abstract
Currently, there is an effort to predict relapse by follow-up monitoring of MRD and subsequently to begin the treatment of the patients during their clinical and hematological remission prior to overt hematological relapse. Expression of WT1 in AML is known to be independently associated with significant inferior response to therapy and short survival outcome. Follow-up monitoring of WT1 gene expression during or after therapy would be a valuable predictive marker for early recurrence or relapse of AML disease. This pilot study evaluated newly diagnosed and post-induction or consolidation chemotherapy of AML patients who were registered with the Oncology Clinics of the Aga Khan University Hospital, Karachi. High WT1 burden (> 5000 copies/ml) in 2 patients was indicative of early recurrence of the disease along with shorter disease-free and overall survival. Low WT1 expression (< 200 copies/ml) in 2 patients after induction and consolidation therapy, respectively, was suggestive of better prognosis.
Publication Details
Page(s) 441-442
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 26, Issue: 5, Year: 2016

Request the full text from PASTIC

References
VardimanJW,ThieleJ,ArberDA,Brunning., 2009.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,Blood 114 937 -51
MiglinoM,ColomboN,PicaG,GrassoR,ClavioM., 2011.WT1 over expression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia,Leukem Lymph 52 1961 -9
QinY,ZhuH,JiangB,LiJ,LuX, 2009.Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease,Leuk Res 33 384 -90
SakamotoY,MariyaY,SasakiS. WT1, 2009.mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia,Tohoku J Exp Med 219 169 -76
ArefS,El-Sharawy,SabryM,RaoufDA, 2013.Prognostic relevance of Wilms tumor 1 (WT1) gene Exon 7 mutations in-patient with cytogenetically normal acute myeloid leukemia,Indian J Hematol Blood Transfuse 10 1007 -13
2012.´a H, Maalaufov´a-Soukupov´a J. Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression,Exp Ther Med 3 129 -33
0

Citations

0

Downloads

170

Views